HT
BCRX icon

HAP Trading’s BioCryst Pharmaceuticals BCRX Stock Holding History

HAP Trading’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14,300
Closed -$58K – 1522
2022
Q3 		$58K Sell
14,300
-1,100
-7% -$14.2K ﹤0.01% 938
2022
Q2 		$80K Sell
15,400
-11,100
-42% -$115K ﹤0.01% 942
2022
Q1 		$57K Sell
26,500
-121,900
-82% -$1.96M ﹤0.01% 1218
2021
Q4 		$1.25M Buy
148,400
+17,500
+13% +$232K 0.03% 413
2021
Q3 		$1.2M Buy
130,900
+70,600
+117% +$1.11M 0.04% 416
2021
Q2 		$123K Buy
60,300
+34,400
+133% +$467K ﹤0.01% 1150
2021
Q1 		$84K Buy
25,900
+8,400
+48% +$86.6K ﹤0.01% 1008
2020
Q4 		$48K Buy
+17,500
New +$90.2K ﹤0.01% 1418
2020
Q3 		– Sell
-14,400
Closed -$11K – 1581
2020
Q2 		$11K Buy
+14,400
New +$57.5K ﹤0.01% 1430

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

HAP Trading's BCRX Position: Q4 2022 in Review

HAP Trading sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2022, closing a stake of 17,834 shares — an estimated $222K sold.

HAP Trading first reported a position in BCRX in Q4 2016 and held it in 7 quarters. The position peaked at $1.33M in Q4 2021. 230 funds tracked by Wall St. Rank hold BCRX as of Q4 2022.

  • HAP Trading reported no remaining BioCryst Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • HAP Trading sold 17,834 BioCryst Pharmaceuticals shares in Q4 2022, an estimated $222K.
  • HAP Trading first reported a position in BioCryst Pharmaceuticals in Q4 2016 and held it in 7 quarters.
  • HAP Trading's BioCryst Pharmaceuticals position peaked at $1.33M in Q4 2021.
  • 230 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2022.

Based on HAP Trading's 13F filing for Q4 2022, filed 14 Feb 2023.